Autophagy, meaning “self-eating,” is a tightly regulated process that allows cells to break down damaged proteins, defective mitochondria, and other unwanted components. The material is enclosed within structures called autophagosomes, which later fuse with lysosomes containing digestive enzymes. The resulting molecular building blocks can be reused for energy and repair. Under normal conditions, autophagy protects cells from stress. In cancer, however, the same survival mechanism can become a powerful defense against chemotherapy.

Cisplatin resistance in gastric cancer does not arise from a single molecular defect. Tumor cells may increase their ability to repair cisplatin-induced DNA damage, reduce the accumulation of the drug, alter pathways that control apoptosis, or reshape the surrounding tumor microenvironment. Changes in cellular metabolism and signaling can further support survival. According to the review, autophagy intersects with many of these mechanisms, helping cancer cells withstand the metabolic and genetic damage caused by treatment.

The relationship between autophagy and cancer is complex because the process can have opposite effects. Excessive or uncontrolled autophagy may contribute to a form of cellular destruction, particularly when cancer cells are exposed to severe stress. More commonly, however, moderate autophagy acts as a protective response. By removing damaged mitochondria and supplying nutrients during treatment, it can prevent the accumulation of toxic cellular components and delay the onset of apoptosis. The biological outcome therefore depends on the intensity, timing, and molecular context of autophagy within each tumor.

The review discusses several existing medicines that could be repurposed or combined with cisplatin to manipulate this process. Chloroquine, for example, interferes with the function of lysosomes and can block the later stages of autophagy, preventing cancer cells from completing the recycling cycle. Metformin, a widely used diabetes drug, may influence autophagy through energy-sensing pathways such as AMP-activated protein kinase and the mammalian target of rapamycin. Other medicines considered include diclofenac, omeprazole, ubenimex, and bortezomib, each of which may affect autophagy or related stress-response networks through distinct mechanisms.

The review also highlights natural compounds with potential activity against cisplatin-resistant gastric cancer. Glycyrrhizin, baicalein, red ginseng polysaccharide, and α-mangosteen are among the candidates discussed. Laboratory studies suggest that such compounds may alter oxidative stress, inflammatory signaling, mitochondrial function, or autophagy-related proteins. However, their presence in a review does not mean that they are proven clinical treatments. Their effectiveness, optimal dosage, pharmacological behavior, and safety alongside cisplatin will require careful validation in animal studies and controlled human trials.

At the molecular level, researchers are investigating the signaling networks that determine whether autophagy protects or eliminates tumor cells. These include pathways controlled by mTOR, AMPK, PI3K, AKT, and other regulators of cellular growth and metabolism. Transcription factors, microRNAs, and proteins involved in autophagosome formation may also influence treatment response. Mapping these networks could allow researchers to identify tumors that rely heavily on protective autophagy and selectively target that vulnerability, rather than applying the same autophagy-modifying strategy to every patient.

The authors further describe the possibility of combining autophagy modulation with immunotherapy, radiotherapy, and precision medicine. Autophagy can influence the release of tumor antigens, immune-cell activity, and the inflammatory environment surrounding a tumor, potentially affecting how effectively the immune system recognizes malignant cells. Radiation can also generate cellular damage that activates autophagy, raising the possibility that carefully timed inhibition or stimulation could improve treatment. Such combinations would need to be designed with precision, since blocking autophagy in healthy tissues or immune cells could produce unwanted effects.

The central message of the review is that autophagy is neither simply a friend nor an enemy of cancer therapy. Its role changes according to tumor genetics, treatment conditions, and the stage of the cellular response. Future strategies may rely on biomarkers that reveal whether autophagy is operating as a survival mechanism in an individual patient’s tumor. By matching cisplatin with the right autophagy-modulating agent, researchers hope to prevent cancer cells from repairing themselves, maintaining energy supplies, and escaping programmed cell death. The approach remains under investigation, but it offers a scientifically grounded strategy for confronting one of gastric cancer’s most persistent clinical challenges.

Subject of Research: Autophagy as a therapeutic target for cisplatin-resistant gastric cancer.

Article Title: Autophagy as a therapeutic target for cisplatin-resistant gastric cancer

Web References: Genes & Diseases: https://www.sciencedirect.com/journal/genes-and-diseases ; DOI: https://doi.org/10.1016/j.gendis.2025.101992

References: Luling Wei, Yingfei Zhou, Jiashuo Li, Hongzhao Qi, Shasha Wang, “Autophagy as a therapeutic target for cisplatin-resistant gastric cancer,” Genes & Diseases, Volume 13, Issue 5, 2026, Article 101992. DOI: 10.1016/j.gendis.2025.101992

Image Credits: Genes & Diseases

Keywords: gastric cancer, cisplatin resistance, autophagy, chemotherapy, cancer therapy, chloroquine, metformin, precision medicine, apoptosis, molecular oncology

Chemoresistance arises through a complex interplay of genetic, epigenetic, and microenvironmental factors, often resulting in heterogeneous tumor cell populations that survive and proliferate despite treatment. Traditional chemotherapeutic agents, designed to induce apoptosis or disrupt cell division, increasingly encounter cancer cells that evade these lethal mechanisms. The evolving molecular understanding of resistance pathways has catalyzed emerging strategies aimed at overcoming this barrier by integrating insights from genomics, molecular biology, and pharmacology to improve therapeutic responsiveness.

Among these strategies, targeted agents have garnered significant attention due to their ability to selectively inhibit oncogenic drivers and signaling pathways integral to tumor progression and survival. Unlike conventional cytotoxic drugs, targeted therapies offer precision, reducing off-target effects while addressing specific molecular aberrations in cancer cells. However, resistance even to targeted agents develops rapidly, often due to secondary mutations, pathway redundancies, or adaptive feedback mechanisms within tumor cells, necessitating the exploration of combinatorial regimens that can simultaneously address multiple resistance mechanisms.

Combinatorial therapies, leveraging the synergistic potential of combining chemotherapeutics with targeted agents or immunomodulatory drugs, seek to dismantle the multifactorial defenses cancer cells wield. By co-targeting metabolic pathways, apoptotic regulators, and microenvironmental interactions, these regimens strive to prevent or delay resistance onset, thereby enhancing clinical outcomes. Advances in precision medicine further enable the customization of these therapeutic combinations based on an individual patient’s molecular tumor profile, increasing the likelihood of response and minimizing unnecessary toxicity.

The tumor microenvironment (TME) plays an indispensable role in mediating chemoresistance, acting as a dynamic niche that nurtures malignant cells and shelters them from therapeutic assault. Components of the TME, including stromal fibroblasts, immune cells, extracellular matrix constituents, and signaling molecules, engage in bidirectional crosstalk with tumor cells, facilitating survival signaling and metabolic reprogramming. Hypoxia, acidosis, and nutrient deprivation within the TME trigger adaptive cellular responses that enhance drug efflux, DNA repair, and anti-apoptotic pathways, cumulatively fostering a resistant phenotype.

Exosomes, nanoscale extracellular vesicles secreted abundantly by cancer and stromal cells within the TME, have emerged as pivotal mediators of chemoresistance. These vesicles transport a cargo of proteins, nucleic acids, and metabolites that modulate recipient cells’ behavior, orchestrating intercellular communication that promotes survival, invasion, and resistance. The horizontal transfer of drug efflux pumps, anti-apoptotic factors, and microRNAs via exosomes contributes to a resistant ecosystem, expanding the therapeutic challenge beyond individual cancer cells to the tumor community as a whole.

Metabolic reprogramming within cancer cells also supports chemoresistance by facilitating adaptive shifts in energy production and biosynthesis pathways. Tumors often exhibit enhanced glycolysis, glutaminolysis, and lipid metabolism alterations, which provide both the energetic and anabolic requirements necessary for rapid proliferation and survival under therapeutic stress. These metabolic adaptations can neutralize drug-induced oxidative stress, support detoxification, and contribute to the maintenance of stem-like cancer cell populations inherently more resistant to treatment.

Recent advances in molecular biology and high-throughput genomics have illuminated numerous targets within these resistance pathways, enabling the development of novel agents that disrupt chemoresistant mechanisms directly. Small molecules, monoclonal antibodies, and RNA-based therapeutics designed to inhibit exosome production, modulate metabolic enzymes, or reprogram immune components of the TME are under rigorous exploration. These innovative therapeutics, especially when employed in rationally designed combinations, hold promise in circumventing resistance and achieving durable treatment responses.

Moreover, technologies such as single-cell sequencing and advanced imaging modalities are revolutionizing the capacity to monitor tumor evolution and resistance dynamics in real time. These tools facilitate the early detection of resistant clones and enable timely therapeutic adjustments, transforming cancer treatment from a one-size-fits-all approach to a dynamic, adaptive process tailored to tumor heterogeneity. Incorporating biomarkers predictive of resistance into clinical practice enhances patient stratification and guides the application of next-generation therapeutic strategies.

Despite these advances, the clinical management of chemoresistance remains an arduous endeavor. Persistent challenges include the plasticity of cancer cells, the redundancy of signaling networks, and the protective impact of the TME, all of which conspire to thwart even the most sophisticated interventions. Consequently, ongoing research emphasizes a multidisciplinary approach, integrating oncology, molecular genetics, pharmacology, and bioinformatics, to develop holistic frameworks that anticipate and neutralize resistance mechanisms.

Ultimately, overcoming chemoresistance necessitates a paradigm shift from reactive to proactive cancer treatment. This involves preemptive therapeutic designs that anticipate resistance pathways, alongside real-time monitoring and adaptable treatment regimens. The integration of emerging therapeutic modalities—targeted drugs, immune checkpoint inhibitors, metabolic modulators, and exosome blockers—within precision medicine protocols heralds a new frontier. These advances aspire not only to extend survival but to improve quality of life by mitigating the toxicities associated with ineffective treatments.

In conclusion, chemoresistance represents one of the most insidious barriers to conquering cancer, intricately woven through molecular, cellular, and environmental interactions. Scientific innovations unraveling these complexities are paving the way toward robust therapeutic strategies that circumvent resistance and transform cancer from a fatal disease into a manageable condition. As research continues to dissect the molecular underpinnings of chemoresistance, the hope of achieving long-term remission and improved survival outcomes for cancer patients worldwide becomes increasingly attainable.

Subject of Research: People
Article Title: Chemoresistance: The hidden barrier in cancer treatment
News Publication Date: 27-Jan-2026
Web References: http://dx.doi.org/10.1016/j.cpt.2025.07.001
Keywords: Clinical medicine